Design: Macro TSH is a large molecular-sized TSH that is mostly a complex of TSH and IgG. Patients with macro TSH have elevated serum TSH and normal free thyroxine levels, mimicking subclinical hypothyroidism. The aim of this study was to clarify the degree of cross-reactivity of macro TSH to different commercial immunoassay systems. Methods: Screening for macro TSH was done using a polyethylene glycol (PEG) method and confirmed with gel filtration chromatography in serum samples from 1901 patients with subclinical hypothyroidism. Interference due to human anti-mouse antibodies (HAMA) was examined using HAMA blockers. TSH was measured with an enzyme immunoassay for the analysis of macro TSH. Serum TSH values in patients with macro TSH were also determined with the widely used commercial immunoassay platforms Elecsys, Centaur and Architect, and the detectability of macro TSH was compared among them. Results: Gel filtration chromatography was performed with 174 serum samples with PEG-precipitable TSH ratios O75%. Twenty serum samples were found to contain large molecular-sized TSH, five of which were due to interference by HAMA. The prevalence of macro TSH was eventually 0.79% (15/1901). Commercial immunoassay systems variably recognized macro TSH. The Architect TSH immunoassay platform was the least reactive to macro TSH, but still recognized it in 60% of macro TSH-containing serum samples. Conclusions: There were no commercial TSH immunoassay platforms that did not cross-react with macro TSH. Screening for macro TSH should be performed before hormone replacement therapy is initiated for subclinical hypothyroidism.
Introduction
Subclinical hypothyroidism is a condition where serum thyroid stimulating hormone (TSH) levels are elevated but thyroid hormone levels are within the reference range (1) . It is often present in patients with chronic thyroiditis when their thyroid function is maintained at normal levels by increased TSH secretion. The prevalence of subclinical hypothyroidism has been reported as being present in 4-10% of the adult population, depending on the TSH cut-off and assay platform (1) . However, the prevalence might be lower, since it has been reported that the direct analogue immunoassay for free thyroxine (T 4 ) measurement results in a significant proportion of patients being misclassified as having subclinical hypothyroidism (2) .
We previously reported that macro TSH exhibited laboratory data similar to that of subclinical hypothyroidism; that is, elevated serum TSH but normal thyroid hormone levels (3) . Macro TSH has a molecular mass O150 kDa and is distinct from 28 kDa monomeric TSH on gel filtration chromatography. Due to its large molecular size, the clearance of macro TSH may be delayed and it can accumulate in the circulation, leading to elevated serum TSH levels. Because the bioactivity of macro TSH is low (3), thyroid hormone levels are normal despite elevated TSH levels. The pathogenesis of macro TSH is not fully understood, but it is mostly a complex of TSH with IgG (3, 4, 5, 6, 7, 8, 9, 10, 11) .
In patients with subclinical hypothyroidism, hormone replacement therapy is usually initiated when serum TSH levels are O10 mIU/l (1). Recommendation for pregnant women with subclinical hypothyroidism is to receive T 4 when their serum TSH levels are O2.5 mIU/l to prevent complications during pregnancy, including miscarriage (12, 13, 14) . However, a recent review suggests a more cautious approach based on insufficient evidence (15) . Because macro TSH is regarded to be biologically inactive, replacement therapy for patients with elevated TSH levels due to macro TSH leads to mismanagement. Replacement therapy continues throughout life; thus, it is very important to distinguish elevated serum TSH levels caused by macro TSH from that caused by monomeric TSH.
Macro TSH has several similarities to macroprolactin (macro PRL) in laboratory findings (16, 17, 18, 19, 20, 21, 22) . Macro PRL with a molecular weight O150 kDa is mostly a complex of PRL with IgG, especially anti-PRL autoantibodies, often causing hyperprolactinemia. The prevalence of macroprolactinemia in patients with hyperprolactinemia is reportedly 9.7-29%, depending on the immunoassay platform. Variable detectability of macro PRL among different immunoassay systems has been reported (19) .
Screening for subclinical hypothyroidism assumes that the immunoassays used to measure TSH can give clinically relevant results irrespective of the different immunoassay systems. In this study, we investigated the presence of macro TSH in patients with subclinical hypothyroidism and compared the detectability of macro TSH among an enzyme immunoassay (EIA) and three commonly used immunoassay systems: Elecsys, Centaur and Architect (23, 24, 25, 26) . The aim of this study was to find a suitable TSH assay platform that did not recognize macro TSH so that we could properly evaluate patients' thyroid function by their serum TSH results.
Subjects and methods

Patients
Among patients whose sera were submitted to the laboratory at Kobe City General Hospital for thyroid function tests between 2012 and 2015, 1901 patients (785 men and 1116 women, aged 64.4G17.7 years) were diagnosed with subclinical hypothyroidism. Blood was drawn into the vacuum blood collection tubes (Venoject, Terumo, Tokyo, Japan) in the morning and the serum was separated for the analysis of thyroid function. This study was approved by the Clinical Research Review Board of Kobe City General Hospital.
TSH assays
The concentrations of TSH and free T 4 in sera were measured with the Elecsys immunoassay using the Cobas e411 analyzer (Roche Diagnostics GmbH). The concentration of TSH was also measured with an EIA that was established in our laboratory (3) . In brief, we used human TSH beta monoclonal antibody (10-T25C, Fitzgerald Industries International, Suite, MA, USA) for the capture antibody and human TSH beta monoclonal antibody (10-T25B, Fitzgerald) for the detection antibody. TSH was sandwiched between a capture-antibody-coated polystyrene ball and the detection-antibody HRP conjugate. The HRP activity bound to the ball was assayed in a reaction with 3-(p-hydroxyphenyl) propionic acid (Aldrich Chemical Co. Milwaukee, WI, USA) as a substrate by measuring fluorescence intensity using a spectrofluorophotometer (FP-6200ST; JASCO Co, Tokyo, Japan), with excitation at 320 nm and emission at 405 nm.
Based on a serum sample with a total TSH concentration of 4.5 mIU/l, the intra-and inter-assay coefficients of variation were 3.5 and 5.2% respectively. Serum TSH levels in 20 patients whose sera contained large molecular-sized TSH on gel chromatography were also measured with the ADVIA Centaur XP immunoassay system (Siemens Healthcare Diagnostics, Munich, Germany) and the Architect TSH immunoassay on the Architect i2000 analyzer (Abbot Diagnostics) in addition to the EIA and Elecsys immunoassays. All immunoassays for TSH were standardized to the Second International Reference Preparation (WHO80/558). Subclinical hypothyroidism was diagnosed based on elevated TSH (O4.0 mIU/l) determined by EIA and normal free T 4 (0.81-1.58 ng/dl) levels.
Polyethylene glycol precipitation
To screen for macro TSH in 1901 patients with subclinical hypothyroidism, we used the polyethylene glycol (PEG) precipitation method as previously reported (3). In brief, serum samples (50 ml) were treated with 50 ml of 25% PEG (the final concentration of PEG; 12.5%) to precipitate g-globulin fractions, and with 50 ml of water for total TSH. TSH in the supernatant of PEG-treated sera and watertreated sera were designated as free and total TSH, respectively. The PEG-precipitable TSH (%), which may be increased in sera containing macro TSH, was calculated as follows: (total TSH K free TSH)/total TSH!100. The PEG-precipitable TSH ratio in 1901 sera was 61.7G10.3%.
Gel filtration chromatography
Among the 1901 serum samples, 174 sera with a PEGprecipitable TSH ratio O75% (meanC1.3 S.D.) and 20 controls with PEG-precipitable TSH !60% were subjected to gel filtration chromatography to evaluate them for the presence of macro TSH. Gel filtration chromatography was performed with a 1!65 cm column of Ultrogel AcA 44 (IBF, La Garenne, France) equilibrated with 0.01 mol/l sodium phosphate buffer (pH 7.0), which contained 0.1 mol/l NaCl, 0.1% (w/v) BSA, and 0.01% (w/v) NaN 3 . Serum samples (50-500 ml) were applied to the column, and 1-ml fractions were collected for TSH measurements. The column was calibrated with various molecular weight markers (Sigma). The ratio of large molecular-sized TSH in control sera was 0.31G0.39%.
Human anti-mouse antibodies
The presence of human anti-mouse antibodies (HAMA) was examined using three HAMA blockers; mouse whole serum (MP-Biomedicals, Santa Ana, CA, USA), mouse IgG (THBR1, Cosmobio Co., Tokyo, Japan) and mouse IgM (THBR2, Cosmobio). TSH concentrations were measured in the presence and absence of HAMA blockers in 20 serum samples containing large molecular-sized TSH. When TSH concentrations decreased to the reference range in the presence of HAMA blockers, the elevated TSH levels were judged as spurious results due to interference by HAMA.
Statistical analysis
All measurements are expressed as meansGS.D. and values greater than the meanC1.96 S.D. were considered to be significantly elevated.
Results
Gel filtration chromatography was performed with 174 serum samples with PEG-precipitable TSH ratios O75% to assess the presence of macro TSH. A significant amount of large molecular-sized TSH (MW O150 kDa) (68.6G25.9%) and a small amount of 28 kDa monomeric TSH were observed in 20 patients as shown in Fig. 1 . The addition of HAMA blockers in the EIA system lowered the TSH levels to the reference range in five of 20 serum samples, suggesting that interference by HAMA caused spuriously elevated TSH levels in these five serum samples. Eventually, 15 patients were diagnosed as having macro TSH and its prevalence in subclinical hypothyroidism was 0.79% (15/1901) .
The clinical characteristics of 15 patients with macro TSH are shown in Table 1 . Samples from elderly patients were predominant, but there were samples from two women of childbearing age (cases 4 and 8). The PEGprecipitable TSH ratio was 89.2G8.9% and the large molecular-sized TSH ratio on gel chromatography was 66.2G27.3%. Free TSH levels were all within the reference range except for case 12, who had a slightly elevated value.
Serum total TSH levels in 15 patients with macro TSH determined by EIA, Elecsys, Centaur and Architect, together with monomeric TSH levels, are shown in Fig. 2 . Serum TSH levels were all elevated in sera from 15 patients with macro TSH by EIA. Commercial TSH immunoassays variably recognized macro TSH. Among 15 patients with macro TSH, serum TSH levels were above the reference range due to macro TSH in all but cases 1, 7, and 10 with Elecsys; 1, 2, 5, 7, and 10 with Centaur; and 1, 2, 5, 7, 10, and 12 with Architect. Cases 4 and 8 were women of childbearing age and macro TSH was recognized by all three commercial assay systems. Architect was the least cross-reactive to macro TSH, but still recognized it in nine of the 15 serum samples containing macro TSH. Figure 1 Representative profiles of the gel filtration chromatography of serum TSH in patients with macro TSH and controls.
A significant amount of large molecular-sized TSH (MW O150 kDa) (68.6G25.9%) and a small amount of 28 kDa monomeric TSH were observed in patients with macro TSH (Fig. 1A) , while almost all TSH immunoreactivity (99.7G0.39%) was eluted at 28 kDa in controls (Fig. 1B) .
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Because the PEG precipitation was performed using the in-house EIA, we examined whether the procedure was valid with the commercial assays employed. The PEGprecipitable TSH ratios determined by EIA, Elecsys, Centaur and Architect are shown in Table 2 . In controls, non-specific precipitation of TSH was found to be !70% in all four immunoassay systems. In patients with macro TSH, the PEG-precipitable TSH ratios determined by EIA and the three commercial immunoassay systems were all significantly elevated. In cases 2 and 5, whose serum TSH levels determined by Centaur and Architect were within the reference ranges, the ratios were significantly elevated, suggesting that macro TSH in these patients might also be recognized by both systems.
The clinical characteristics of five patients with HAMA are shown in Table 3 . Measurement of TSH levels with some commercial immunoassays produced spuriously higher results than their references due to HAMA; these included case 18 with the Elecsys and Centaur immunoassays and case 20 with the Centaur and Architect immunoassays.
Among 1901 patients with subclinical hypothyroidism, 13 had PEG-precipitable TSH ratios O90% and all had either macro TSH (nZ10) or HAMA (nZ3).
Discussion
This study demonstrated that i) macro TSH was present in 0.79% of patients with subclinical hypothyroidism; ii) three commonly used immunoassay systems, Elecsys, Centaur and Architect TSH platforms, variably recognized macro TSH; and iii) the Architect TSH platform was the least reactive to macro TSH, but still recognized it in 60% of macro TSH-containing serum samples. 
European Journal of Endocrinology
There are several possibilities why some assays recognize macro TSH and others do not. We previously reported that macro TSH in most cases was a complex of TSH with anti-TSH autoantibodies (3) . If the epitopes for the reagent's antibodies are already occupied by anti-TSH autoantibodies, the reagent's antibodies cannot bind to the epitope and the assay system may not recognize macro TSH. If the reagent's antibodies recognize the different epitopes for anti-TSH autoantibodies, the assay system could indicate macro TSH. Thus, one of the causes is the nature of the reagent's antibodies. Another possibility is that the nature of macro TSH is heterogeneous like macro PRL (22) , leading to the variable detectability of macro TSH by different immunoassay systems. Because Elecsys, Centaur, Architect and EIA are all sandwich-type immunoassay systems using two different anti-TSH monoclonal antibodies, assay kinetics may not be involved for the variable detectability. Although none of the assay systems succeeded in providing TSH values unaffected by macro TSH in all the serum samples known to contain macro TSH, the performance of the Architect platform was superior to that of the other assay systems examined in this study. Nonetheless, Architect still recognized macro TSH in 60% of macro TSH-containing serum samples.
PEG at a final concentration of 12.5% precipitates gamma-globulins. Because macro TSH is a complex of TSH and IgG in most cases (3, 4, 5, 6, 7, 8, 9, 10, 11) , increased ratios of PEG-precipitable TSH may indicate the presence of macro TSH. In macroprolactinemia, PEG-precipitable PRL O60% (recovery !40%) is usually used for the screening, and the diagnosis is confirmed using gel filtration chromatography (16, 17, 18, 19, 20, 21, 22) . Because the background ratio of PEG-precipitable TSH was high (61.7G10.3%), we took the strategy of setting the cut-off value as 75% (meanC1.3 S.D.) arbitrarily to increase the sensitivity of the screening, and confirming macro TSH by gel filtration chromatography. We found that two-thirds of serum samples containing macro TSH had PEG-precipitable TSH ratios O90% and that all the sera with the ratios O90% had either macro TSH or HAMA. Thus, the presence of macro TSH is strongly suspected when PEG-precipitable TSH ratios are O90%. These findings are also valid using the commercial TSH immunoassay systems. Gel filtration chromatography should be performed if the ratios are O90% or when necessary even if the ratios are between 75 and 90% to confirm the presence of macro TSH. HAMA is an interfering substance in immunoassay systems for several hormones in human sera (27, 28, 29) . It comprises naturally developed anti-mouse protein antibodies in human sera, and binds to mouse-derived monoclonal antibodies in reagents where it bridges the capture-and detection-antibodies, producing a false signal. Because HAMA belongs to the gamma-globulins, it is precipitated with 12.5% PEG, resulting in a high ratio of PEG-precipitable TSH. In addition, because HAMA elutes at the same position as gamma-globulin (O150 kDa), sera containing HAMA behave as if macro TSH existed on gel filtration chromatography. In this study, we observed five patients (0.26%) with HAMA among 1901 patients with subclinical hypothyroidism. Commercial immunoassay systems take some measures to minimize the interference by HAMA, using HAMA blockers, chimeric antibody (human Fc and mouse Fab fragments) or sheep antibody (28) . However, HAMA in two of five serum samples still interfered. We should keep in mind that even commercial TSH immunoassay systems cannot be completely free from interference by HAMA.
Hormone replacement therapy with T 4 persists for a long time. Although the prevalence of macro TSH was higher in elderly people, two patients were of childbearing age. It is thus very important to distinguish elevated serum TSH levels caused by macro TSH from that caused by monomeric TSH in patients with subclinical hypothyroidism. At present, there are no TSH immunoassay platforms that do not cross-react with macro TSH. Therefore, we recommend that when hormone replacement therapy for subclinical hypothyroidism is considered, screening for macro TSH should be performed, especially for women of childbearing age.
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